These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 6148247)

  • 1. Effects of S (+)-3-phenethyl-PP, a putative dopamine autoreceptors agonist with greater autoreceptor selectivity than 3-PPP enantiomers.
    Arnt J; Bøgesø KP; Hyttel J; Larsen JJ; Svendsen O
    Eur J Pharmacol; 1984 Jun; 102(1):91-9. PubMed ID: 6148247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine receptor agonistic and antagonistic effects of 3-PPP enantiomers.
    Arnt J; Bøgesø KP; Christensen AV; Hyttel J; Larsen JJ; Svendsen O
    Psychopharmacology (Berl); 1983; 81(3):199-207. PubMed ID: 6139838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postsynaptic dopamine agonistic effects of 3-PPP enantiomers revealed by bilateral 6-hydroxy-dopamine lesions and by chronic reserpine treatment in rats.
    Arnt J; Hyttel J
    J Neural Transm; 1984; 60(3-4):205-23. PubMed ID: 6441835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential behavioural effects of dopamine agonists in developing rats: a study of 3-PPP enantiomers.
    Arnt J
    Eur J Pharmacol; 1983 Jul; 91(2-3):273-8. PubMed ID: 6617748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological profiles of the putative dopamine autoreceptor agonists 3-PPP and TL-99.
    Martin GE; Haubrich DR; Williams M
    Eur J Pharmacol; 1981 Nov; 76(1):15-23. PubMed ID: 7318920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Behavioural stimulation is induced by separate dopamine D-1 and D-2 receptor sites in reserpine-pretreated but not in normal rats.
    Arnt J
    Eur J Pharmacol; 1985 Jul; 113(1):79-88. PubMed ID: 2931283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP.
    Hjorth S; Carlsson A; Clark D; Svensson K; Wikström H; Sanchez D; Lindberg P; Hacksell U; Arvidsson LE; Johansson A
    Psychopharmacology (Berl); 1983; 81(2):89-99. PubMed ID: 6415751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of the enantiomers of 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP) at dopamine receptor sites.
    Koch SW; Koe BK; Bacopoulos NG
    Eur J Pharmacol; 1983 Sep; 92(3-4):279-83. PubMed ID: 6138267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of the component enantiomers of the putative dopamine autoreceptor agonist, TL-99 (6,7-dihydroxy-2-dimethylamino tetralin) with dopaminergic systems in mammalian brain and teleost retina.
    Williams M; Martin GE; McClure DE; Baldwin JJ; Watling KJ
    Naunyn Schmiedebergs Arch Pharmacol; 1983 Dec; 324(4):275-80. PubMed ID: 6141532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of putative dopamine autoreceptor agonists in pharmacological models related to dopaminergic and neuroleptic activity.
    Arnt J; Christensen AV; Hyttel J; Larsen JJ; Svendsen O
    Eur J Pharmacol; 1982 Dec; 86(2):185-98. PubMed ID: 6130958
    [No Abstract]   [Full Text] [Related]  

  • 11. Central dopaminergic properties of HW-165 and its enantiomers; trans-octahydrobenzo(f)quinoline congeners of 3-PPP.
    Hjorth S; Svensson K; Carlsson A; Wikström H; Andersson B
    Naunyn Schmiedebergs Arch Pharmacol; 1986 Jul; 333(3):205-18. PubMed ID: 3762735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence.
    Clark D; Hjorth S; Carlsson A
    J Neural Transm; 1985; 62(1-2):1-52. PubMed ID: 3894582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On the mode of action of 3-(3-hydroxyphenyl)-N-n-propylpiperidine, 3-PPP, and its enantiomers. With particular reference to dopaminergic mechanisms in the central nervous system.
    Hjorth S
    Acta Physiol Scand Suppl; 1983; 517():1-52. PubMed ID: 6138921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indolizidine and quinolizidine derivatives of the dopamine autoreceptor agonist 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP).
    Bøgesø KP; Arnt J; Lundmark M; Sundell S
    J Med Chem; 1987 Jan; 30(1):142-50. PubMed ID: 3806591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agonist and antagonist effects of 3-PPP enantiomers on functional dopamine autoreceptors and postsynaptic dopamine receptors in vitro.
    Mulder AH; Draper R; Sminia P; Schoffelmeer AN; Stoof JC
    Eur J Pharmacol; 1985 Jan; 107(3):291-7. PubMed ID: 3979429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine (DA) autoreceptor efficacy of 3-PPP enantiomers after short-term synaptic DA deprivation.
    Hjorth S; Clark D; Carlsson A
    Eur J Pharmacol; 1988 Aug; 152(3):207-15. PubMed ID: 3146512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential electrophysiological effects of 3-PPP and its enantiomers on dopamine autoreceptors and postsynaptic receptors.
    Bergstrom DA; Carlson JH; Bromley SD; Jackson DM; Walters JR
    Eur J Pharmacol; 1986 May; 124(1-2):75-84. PubMed ID: 3720847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential agonist profile of the enantiomers of 3-PPP at striatal dopamine autoreceptors: dependence on extracellular dopamine.
    Clark D; Salah RS; Galloway MP
    Synapse; 1991 Jul; 8(3):169-76. PubMed ID: 1948667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine receptors involved in prolactin secretion pharmacologically characterized by means of 3-PPP enantiomers.
    Eriksson E; Modigh K; Carlsson A; Wikström H
    Eur J Pharmacol; 1983 Dec; 96(1-2):29-36. PubMed ID: 6662196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different actions of TL-99 and 3-PPP in producing contraversive turning in the 6-OHDA-lesioned rat.
    Martin GE; Jones JH; Bendesky RJ
    Eur J Pharmacol; 1983 Sep; 92(3-4):275-8. PubMed ID: 6138266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.